Given that the importance of cancer immunotherapy with immune checkpoint inhibitors, we further investigated the difference in the expression of immune checkpoints between the high-risk and low-risk groups and the result revealed that all 30 immune checkpoints were more active in the low-risk group, including PDCD-1 (PD-1), CD274 (PD-L1), CTLA4, LAG3, and BTLA (Fig. 8C). This evidence concerns the gene CTLA4 and cancer.